Page last updated: 2024-09-04
canertinib dihydrochloride and tandutinib
canertinib dihydrochloride has been researched along with tandutinib in 1 studies
Compound Research Comparison
Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (tandutinib) | Trials (tandutinib) | Recent Studies (post-2010) (tandutinib) |
---|---|---|---|---|---|
31 | 13 | 6 | 69 | 5 | 41 |
Protein Interaction Comparison
Protein | Taxonomy | canertinib dihydrochloride (IC50) | tandutinib (IC50) |
---|---|---|---|
Integrin beta-3 | Homo sapiens (human) | 0.22 | |
Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | 3.43 | |
Integrin alpha-IIb | Homo sapiens (human) | 0.22 | |
Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.149 | |
Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1867 | |
Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.17 | |
Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.2 | |
Fibroblast growth factor receptor 2 | Homo sapiens (human) | 0.17 | |
Fibroblast growth factor receptor 4 | Homo sapiens (human) | 0.17 | |
Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.17 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 2.07 | |
Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.9345 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.2 | |
Cannabinoid receptor 2 | Rattus norvegicus (Norway rat) | 0.2 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Russu, WA; Shallal, HM | 1 |
Other Studies
1 other study(ies) available for canertinib dihydrochloride and tandutinib
Article | Year |
---|---|
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |